WASHINGTON – October 28, 2026 -- LUNGevity Foundation and patient advocacy group RETpositive have awarded a combined $340,000 to two research projects targeting drug resistance in RET-positive cancers, where tumors eventually outlast the two FDA-approved RET tyrosine kinase inhibitors (TKIs).